Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LIMITED SPON ADR EACH REP 300 ORD

3.55
-0.7400-17.25%
Post-market: 3.42-0.1344-3.79%19:42 EDT
Volume:1.54M
Turnover:4.82M
Market Cap:41.94M
PE:-0.93
High:3.94
Open:2.87
Low:2.73
Close:4.29
52wk High:16.25
52wk Low:2.73
Shares:11.81M
Float Shares:8.29M
Volume Ratio:47.20
T/O Rate:18.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8088
EPS(LYR):-3.6237
ROE:-92.10%
ROA:-28.33%
PB:1.16
PE(LYR):-0.98

Loading ...

NASDAQ Trade Halt Continues Volatility Trading Pause at 09:37 Am

Reuters
·
Jul 24

Radiopharm announces $4.1M registered direct offering

TIPRANKS
·
Jul 24

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

GlobeNewswire
·
Jul 24

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

GlobeNewswire
·
Jul 22

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

GlobeNewswire
·
Jul 22

NASDAQ Trade Halt Halt News Pending at 07:56 Pm

Reuters
·
Jul 22

Radiopharm Theranostics Ltd : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $16

THOMSON REUTERS
·
Jun 04

Radiopharm initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Jun 04

Radiopharm Theranostics Reports Business Update

GlobeNewswire
·
Apr 23

Radiopharm announces new data from Phase 0/1 HEAT trial

TIPRANKS
·
Apr 20

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

GlobeNewswire
·
Apr 20

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

GlobeNewswire
·
Apr 08

Buy Rating on RADX Driven by Promising RAD 101 Phase 2b Imaging Data and Clear 2026 Clinical Milestones

TIPRANKS
·
Mar 27

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

GlobeNewswire
·
Mar 24

Analysts Are Bullish on These Healthcare Stocks: Schrodinger (SDGR), Radiopharm Theranostics Limited Sponsored ADR (RADX)

TIPRANKS
·
Mar 07

Radiopharm doses first patient in Phase 1/2a study of BetaBart

TIPRANKS
·
Feb 24

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)

GlobeNewswire
·
Feb 24

Analysts Conflicted on These Healthcare Names: Resmed (RMD), Radiopharm Theranostics Limited Sponsored ADR (RADX) and Stryker (SYK)

TIPRANKS
·
Jan 30

Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027

Benzinga
·
Jan 28